Senescent Cell Mitigation refers to therapeutic strategies aimed at selectively eliminating or neutralizing senescent cells that accumulate with age and contribute to chronic, low-grade inflammation. These dysfunctional cells secrete pro-inflammatory cytokines that actively impair local and systemic endocrine signaling. Our focus is on removing this source of physiological impedance. Mitigation seeks to restore a healthier cellular environment.
Origin
This field stems from geroscience, which identifies cellular senescence as a core, modifiable hallmark of aging that negatively impacts tissue function and longevity. The mitigation approach is proactive, targeting the mechanism of age-related decline rather than just the resulting symptoms. It represents a fundamental shift in longevity science.
Mechanism
Mitigation protocols often employ senolytic agents, which selectively induce apoptosis in senescent cells, or senomorphic agents, which alter their detrimental Senescence-Associated Secretory Phenotype (SASP). By reducing the inflammatory burden from these cells, we indirectly improve the microenvironment surrounding endocrine tissues. This reduction in chronic inflammation can significantly enhance hormone receptor sensitivity and overall metabolic signaling fidelity.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.